Pain palliation in patients with bone metastasis using MR-guided focused ultrasound with conformal bone system: A preliminary report
Mi-Suk Park1, Bio Joo1, Soo Hyun Lee1, Hye Jin Choi1, Young Tag Oh1, Itay Rachmilevitch2, and Ori Atar2
1Yonsei University Medical School, Seoul, Seoul, Korea, 2Insightec, Israel, Israel, Israel

Title: Pain palliation in patients with bone metastasis using MR-guided focused ultrasound with conformal bone system: A preliminary report

Introduction: MR-guided Focused Ultrasound (MRgFUS) with conformal bone system (CBS) integrates new features that were developed for the bone application. The system to be used in this study utilizes new software, a conformal transducer and patient interface that increases coupling by using a cooled porous membrane that in turn enhances safety. However, there has been no report about the safety and effectiveness of the CBS for pain palliation in patients with bone metastasis. The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and effectiveness of this treatment using this ExAblate CBS in the treatment of pain resulting from metastatic bone tumors.

Methods: This study was performed as part of a clinical trial titled “Study to Evaluate the safety and Initial Effectiveness of ExAblate MR Guided Focused Ultrasound Surgery in the Treatment of Pain Resulting from Metastatic Bone Tumors with the ExAblate 2100 Conformal System: Feasibility Study”. Five patients with painful bone metastases underwent the MRgFUS with CBS procedure in one institution. Treatment safety was evaluated by assessing the device-related complications. Effectiveness of pain palliation was evaluated using the visual analog pain score.

Results: Six procedures were performed in five patients. Mean follow up time was 3.3 months. One patient reported complete response in pain relief. Average VAS score was reduced from 5.8 prior to treatment to 0.8 at 3 months post treatment. One patient had second degree skin burn.

Conclusion: MRgFUS with CBS is effective for pain palliation in patients with bone metastasis. Regarding safety issues, there were two suspected adverse event. Further study is needed to resolve this complication.

Acknowledgement: This work was supported by a grant InSightec (BM012).